{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:09:50Z","timestamp":1698642590139},"reference-count":41,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T00:00:00Z","timestamp":1222646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Although no consensus on the exact dosing schedule of prophylaxis in non\u2010inhibitor haemophilia patients has been achieved, regular administration of factor VIII (FVIII) or factor IX (FIX) concentrates is currently accepted as the most effective treatment model in order to prevent sick days, hospital stays and the development of arthropathy in patients with severe haemophilia. The basis for prophylaxis has been the idea to increase the plasma levels of FVIII or FIX above 1% thereby improving the haemostasis in severe haemophilia. Current treatment in haemophilia patients with inhibitors includes the use of activated prothrombin complex concentrates and recombinant FVIIa (rFVIIa). Regular administration of such agents has recently repeatedly been reported to decrease the number of joint and muscle bleeds in these patients. Regarding rFVIIa, such an effect was confirmed in a controlled study published in 2007. Although the exact mechanism of action of rFVIIa in this setting is still not clear, it seems reasonable to assume that prophylaxis with rFVIIa will be able to prevent or minimize the development of haemophilic arthropathy. As arthropathy is a long\u2010term complication in haemophilia and the result of repeated joint bleeds, a longer follow\u2010up of patients on regular prophylaxis including measurements of the joint scores, as has been performed in FVIII\/FIX prophylaxis in non\u2010inhibitor patients, will be required for a definite conclusion.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01886.x","type":"journal-article","created":{"date-parts":[[2008,9,29]],"date-time":"2008-09-29T07:54:30Z","timestamp":1222674870000},"page":"23-27","source":"Crossref","is-referenced-by-count":2,"title":["Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?"],"prefix":"10.1111","volume":"14","author":[{"given":"U.","family":"HEDNER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"7","article-title":"Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo\u2013skeletal manifestations of haemophilia A and B","volume":"77","author":"Ahlberg \u00c5","year":"1965","journal-title":"Acta Orthop Scand"},{"key":"e_1_2_7_3_2","first-page":"415","article-title":"Purification of human and bovine fibrinogen","volume":"10","author":"Blomb\u00e4ck B","year":"1956","journal-title":"Ark Kemi"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1976.tb16525.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00694.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830180104"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_7_9_2","unstructured":"FeketeL HolstS PeetoomF DeVeberLL.\u201cAuto\u201d factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors.Paper presented at the XIV International Congress of Hematology S\u00e3o Paulo July 16\u201321 1972."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197407252910402"},{"key":"e_1_2_7_11_2","first-page":"3","article-title":"Thrombogenicity associated with factor IX complex concentrates","volume":"28","author":"Lusher JM","year":"1991","journal-title":"Semin Hematol"},{"key":"e_1_2_7_12_2","first-page":"159","article-title":"Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo","volume":"49","author":"White GC","year":"1977","journal-title":"Blood"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1182\/blood.V54.6.1358.1358","article-title":"Effect of prothrombin complex concentrates on factor VIII inhibitor levels","volume":"54","author":"Kasper CK","year":"1979","journal-title":"Blood"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(79)90164-6"},{"issue":"1","key":"e_1_2_7_15_2","first-page":"195a","article-title":"Characterization of active enzymes in Autoplex (abstract)","volume":"10","author":"Bray GL","year":"1995","journal-title":"Blood"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008213030803"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01601.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90259-0"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(98)00026-5"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000169218.15926.34"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-0331-2_15"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00925.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(96)00028-X"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-07-0510"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00553.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1055\/s-0037-1616550","article-title":"Effective prophylaxis with daily recombinant factor VIIa (rFVIIa\u2010NovoSeven) in a child with high titre inhibitors and a target joint","volume":"86","author":"Saxon BR","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_30_2","unstructured":"BlatnyJ KohleroveS ZapletalO FiamoliV PenkaM.rFVIIa is effective alternative to aPCC in prophylaxis of bleeding during immune tolerance protocol in haemophiliac with inhibitor (abstract).Abstract no. P\u2010M\u2010166 XXIst ISTH Congress Geneva July 6\u201311 2007."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00009"},{"key":"e_1_2_7_32_2","unstructured":"Lopez FernandezM Andon SaavedraC Amor OteroMA BattleJ.\u201cPrimary\u201d prophylactic treatment with recombinant activated factor VII (rFVIIa) during immune tolerance in a haemophilic child (abstract).Abstract no. P\u2010M\u2010161 XXIst ISTH Congress Geneva July 6\u201311 2007."},{"key":"e_1_2_7_33_2","unstructured":"Marqu\u00e8s\u2010VerdierA ChaleteixC Souli\u00e9B BayJO.Secondary prophylaxis with recombinant activated factor VII (rFVIIa) in a severe haemophilia A patient with anti\u2010factor VIII inhibitors (abstract).Abstract no. P\u2010T\u2010168 XXIst ISTH Congress Geneva July 6\u201311 2007."},{"key":"e_1_2_7_34_2","doi-asserted-by":"crossref","unstructured":"MolinaMQ BelloIF YusteVJet\u00a0al.Prophylaxis with recombinant FVIIa (abstract).Abstract no. P\u2010T\u2010170 XXIst ISTH Congress Geneva July 6\u201311 2007.","DOI":"10.1111\/j.1538-7836.2007.tb01928.x"},{"issue":"2","key":"e_1_2_7_35_2","article-title":"Prophylaxis with rFVIIa during immune\u2010tolerance treatment in a haemophiliac child with a target joint (abstract)","volume":"12","author":"Tagliaferri A","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01096.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01455.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00817.x"},{"key":"e_1_2_7_40_2","first-page":"111","article-title":"Our experience in Sweden with prophylaxis on haemophilia. Proceedings of the 5th Congress World Federation of Hemophilia, Montreal","volume":"34","author":"Nilsson IM","year":"1968","journal-title":"Bibl Haemat"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00771.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb00973.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01886.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01886.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:34:31Z","timestamp":1694612071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01886.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,29]]},"references-count":41,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01886.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01886.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,29]]}}}